Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €39.50 EUR
Change Today +3.41 / 9.45%
Volume 162.2K
ERYP On Other Exchanges
Symbol
Exchange
EN Paris
As of 11:39 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

erytech pharma (ERYP) Snapshot

Open
€36.19
Previous Close
€36.09
Day High
€39.50
Day Low
€36.15
52 Week High
08/3/15 - €39.50
52 Week Low
08/8/14 - €12.12
Market Cap
272.1M
Average Volume 10 Days
70.8K
EPS TTM
€-1.51
Shares Outstanding
6.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ERYTECH PHARMA (ERYP)

Related News

No related news articles were found.

erytech pharma (ERYP) Related Businessweek News

No Related Businessweek News Found

erytech pharma (ERYP) Details

ERYTECH Pharma, société anonyme develops cancer therapies in France and internationally. The company’s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. It is developing ERY-ASP/GRASPA that consists of red blood cell-encapsulated L-asparaginase, which destroys asparagine inside the red blood cell, preventing allergic reactions and reducing other adverse events. The company is developing ERY-ASP/GRASPA, which is in Phase III clinical trials for treating acute lymphoblastic leukemia; Phase IIb clinical trials for treating acute myeloid leukemia; and Phase I study for the treatment of pancreas cancer. In addition, it explores for other solid tumor indications for ERY-ASP. The company was founded in 2004 and is headquartered in Lyon, France.

42 Employees
Last Reported Date: 05/12/15
Founded in 2004

erytech pharma (ERYP) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €369.6K
Co-Founder, Chief Scientific Officer, Deputy ...
Total Annual Compensation: €265.6K
Director of Pharmaceutical Operations and Dep...
Total Annual Compensation: €66.8K
Compensation as of Fiscal Year 2014.

erytech pharma (ERYP) Key Developments

ERYTECH Pharma Announces Cash Flow Results for the Second Quarter and First Half of 2015

ERYTECH Pharma announced cash flow results for the second quarter and first half of 2015. For the quarter, the net used of cash for operational and investing activities amounted to €3.4 million. For the first half, the net used of cash for operational and investing activities amounted to €6.4 million.

Erytech Pharma Société Anonyme Presents at French Life Science Days conference, Jun-17-2015

Erytech Pharma Société Anonyme Presents at French Life Science Days conference, Jun-17-2015 . Venue: W Hotel, 541 Lexington Avenue, New York, NY 10022, United States.

Erytech Pharma Société Anonyme Presents at BioEquity Europe 2015, May-19-2015 05:00 PM

Erytech Pharma Société Anonyme Presents at BioEquity Europe 2015, May-19-2015 05:00 PM. Venue: InterContinental Vienna, Vienna, Austria.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ERYP:FP €39.50 EUR +3.41

ERYP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ERYP.
View Industry Companies
 

Industry Analysis

ERYP

Industry Average

Valuation ERYP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 112.6x
Price/Book 6.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 104.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERYTECH PHARMA, please visit erytech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.